CN1634588A - Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer - Google Patents

Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer Download PDF

Info

Publication number
CN1634588A
CN1634588A CNA2004100971505A CN200410097150A CN1634588A CN 1634588 A CN1634588 A CN 1634588A CN A2004100971505 A CNA2004100971505 A CN A2004100971505A CN 200410097150 A CN200410097150 A CN 200410097150A CN 1634588 A CN1634588 A CN 1634588A
Authority
CN
China
Prior art keywords
nano carbon
carbon microsphere
medicinal nano
tumor
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004100971505A
Other languages
Chinese (zh)
Other versions
CN1274366C (en
Inventor
杨维稼
孙逸萍
孙汉翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2004100971505A priority Critical patent/CN1274366C/en
Publication of CN1634588A publication Critical patent/CN1634588A/en
Priority to PCT/CN2005/002112 priority patent/WO2006063506A1/en
Application granted granted Critical
Publication of CN1274366C publication Critical patent/CN1274366C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutic nanometer carbon sphere and its application in the preparation process of cancer treatment medicine. The pharmaceutical nanometer carbon sphere and anti tumor drug having biological guide character, making the nanometer carbon sphere as carrier, can be capable of enhancing anti tumor effect considerably, lowering the toxic and side effect of chemical therapeutic and radiation therapeutic drug and deceasing the damage of anti tumor drug to the body normal cell and immune system in the largest extent.

Description

Medicinal nano carbon microsphere and the application in preparation treatment cancer drug thereof
Technical field
The present invention relates to medicinal nano carbon microsphere and the application in preparation treatment cancer drug thereof.Or rather, the present invention relates to a kind of medicinal nano carbon microsphere that has bio-guide character, is used as antitumor drug, a kind of is the antitumor drug with bio-guide character and preparation method thereof of carrier with the medicinal nano carbon microsphere, also relates to this medicinal nano carbon microsphere in the medicine of preparation treatment cancer drug, treatment cardiovascular and cerebrovascular disease and the application in the treatment rheumatic and rheumatoid diseases medicine.
Background technology
The whole world reaches 7,000,000 people because of malignant tumor death every year, about 2,000,000 people of Chinese annual neopathy, and tumor has become one of human main causes of death, and the prevention of cancer and treatment task are very arduous.The main means of treatment cancer are early discoverys at present, excision, but excision can not solve the problem of metastatic lesion.Owing to shift and often to cause postoperative recurrence, so generally after operation, all add with chemotherapy or radiotherapy in case spline is moved.But the effect of chemotherapy and radiation is also undesirable, reason is that the difference of the therapeutic dose of medicine and toxic dose is little, especially the hemopoietic function cell is extremely responsive to change, radiotherapy, causes serious systemic side effects in treatment inevitably, thereby can not life-time service or heavy dose of the use.
Ideal medicine is targetedly medicine to be directed to focal zone to greatest extent, makes the drug level in focal zone and normal cell district very big difference occur, thereby protects normal cell and tissue to preserve from effectively, Here it is targeted drug.Occurred the dosage form of lympha targeted medicine in this respect recently, as used, but domestic and foreign literature does not see that relevant is the report of the targeting preparation of carrier with the medicinal nano carbon microsphere with the targeting preparation of active carbon as carrier.The inventor is through studying for a long period of time and a large amount of test, and the result shows that medicinal nano carbon microsphere has bio-guide character, and tumor is had the obvious suppression effect, and has good medicine carrying effect, has finished the present invention on this basis.
Summary of the invention
First purpose of the present invention provides a kind of medicinal nano carbon microsphere that has bio-guide character, can be used as antitumor drug or carrier.
It is the antitumor drug with bio-guide character and preparation method thereof of carrier with the medicinal nano carbon microsphere that second purpose of the present invention provides a kind of.
The 3rd purpose of the present invention provides the application of medicinal nano carbon microsphere in preparation treatment cancer drug.
The 4th purpose of the present invention provides the application of medicinal nano carbon microsphere in preparation treatment cardiovascular and cerebrovascular diseases medicament.
A further object of the invention provides the application of medicinal nano carbon microsphere in preparation treatment rheumatism, rheumatoid disease medicine.
A kind of medicinal nano carbon microsphere that bio-guide character can be used as antitumor drug or carrier that has provided by the invention is characterized in that this medicinal nano carbon microsphere particle diameter is 2nm-1000nm, and wherein 90% diameter of particle is＜300nm, and its specific surface area is 100-3000M 2/ g, ash is lower than 8%, and loss on drying should be lower than 5%, and lead, cadmium, arsenic, mercury content are lower than 20ppm, and avirulence is answered in the inspection of undue toxicity's inspection technique; The microbial limit test inspection always contains the every gram of bacterium number should be lower than 100.
The raw material that is used to prepare this medicinal nano carbon microsphere can be selected from nano-carbon material, the VXC72 nano carbon microsphere that for example commercially available U.S.'s Cabot (Carbot) company produces, and its characteristic is as shown in table 1:
Table 1
Performance project Unit Index
Specific surface area ????M 2/g ????254
Oil factor ????ML/100g ????192/174
Tinting strength, tinting power ????％ITRB ????87
Particle diameter ????nm ????30
Ash ????％ ????1.0
Loss on drying ????％ ????1.0
The preparation method of medicinal nano carbon microsphere of the present invention is as follows:
With commercially available medicinal nano carbon microsphere 0.1g, add 0.1N hydrochloric acid 5mL, immersion treatment 8 hours, add water 50mL, filter, being washed to PH repeatedly is 6, add 0.1N sodium hydroxide 5mL, handled 8 hours, and filtered, being washed to PH is 8-9, add 0.1N hydrochloric acid 5mL, filter, drying is until the medicinal nano carbon microsphere that obtains to conform to quality requirements.
The invention provides a kind of is the antitumor drug with bio-guide character (being called for short the A preparation) of carrier with the medicinal nano carbon microsphere, it is characterized in that its composition and proportioning are as follows:
Medicinal nano carbon microsphere 5-100mg
Directed agents 0-10mg
Suspending agent 0-30mg
Surfactant 0-15mg
Excipient 0-500mg
Water is an amount of.
Above-mentioned antitumor drug, its feature are that also the raw material for preparing medicinal nano carbon microsphere is selected from nano-carbon material, for example VXC-72; Directed agents is selected from folic acid and its esters, as calcium folinate; Suspending agent is selected from polyvinylpyrrolidone, arabic gum, tragacanth, polyvinyl alcohol Sodium Tvlose, hydroxypropyl emthylcellulose etc., is preferably polyvinylpyrrolidone; Surfactant is selected from tween, polyoxyethylene castor oil, Bo Luoshamu etc., is preferably Bo Luoshamu; Excipient is selected from serum albumin or gamma globulin.
Above-mentioned preparing anti-tumor medicine method comprises the steps:
(1) prepares the medicinal nano carbon microsphere that conforms to quality requirements;
(2) add suspending agent and/or surfactant by proportioning;
(3) add directed agents by proportioning, sonic oscillation was handled 30～60 minutes, autoclaving 30～60 minutes, and packing, embedding, autoclaving 45 minutes obtains the formulation in liquid form finished product;
(4) add excipient by proportioning, lyophilization promptly gets lyophilized powder type finished product under aseptic condition.
It is the antitumor drug with bio-guide character (being called for short the B preparation) of carrier with the medicinal nano carbon microsphere that the present invention also provides another kind of, it is characterized in that its composition and proportioning are as follows:
Medicinal nano carbon microsphere 5-100mg
Directed agents 0-20mg
Anti-tumor active ingredient 1-100mg
Suspending agent 0-30mg
Surfactant 0-15mg
Excipient 0-500mg
Water is an amount of.
Above-mentioned antitumor drug, its feature are that also the raw material of medicinal nano carbon microsphere is selected from nano-carbon material, as VXC72; Directed agents is selected from folic acid and its esters, as calcium folinate; Anti-tumor active ingredient is selected from anti-tumor chemotherapeutic medicine, antitumor radiotherapy medicine, the material, anti-tumour antibody or the incomplete antibody class that suppress tumor-blood-vessel growth, interferon or anticancer polypeptide class etc., is preferably anti-tumor chemotherapeutic and radiotherapy medicine; Suspending agent is selected from polyvinylpyrrolidone, arabic gum, tragacanth, polyvinyl alcohol Sodium Tvlose, hydroxypropyl emthylcellulose etc., is preferably polyvinylpyrrolidone; Surfactant is selected from tween, polyoxyethylene castor oil, Bo Luoshamu etc., is preferably Bo Luoshamu; Excipient is selected from serum albumin or gamma globulin.
Above-mentioned preparing anti-tumor medicine method is characterized in that this method comprises the steps:
(1) prepare the medicinal nano carbon microsphere that conforms to quality requirements:
(2) add suspending agent and/or surfactant and anti-tumor active ingredient, mix homogeneously by proportioning;
(3) add directed agents by proportioning, sonic oscillation was handled 30～60 minutes, autoclaving 30～60 minutes, and packing, embedding, autoclaving 45 minutes obtains the formulation in liquid form finished product;
(4) add excipient by proportioning, lyophilization gets product under aseptic condition.
The present invention also provides the application of this medicinal nano carbon microsphere in preparation treatment cancer drug.
The present invention also provides the application of this medicinal nano carbon microsphere in preparation treatment cardiovascular and cerebrovascular diseases medicament.
The present invention also provides the application of this medicinal nano carbon microsphere in preparation treatment rheumatism, rheumatoid disease medicine.
For back two kinds of application, employed preparation is not for adsorbing the medicinal nano carbon microsphere of anti-tumor active ingredient, the same anticancer preparation of its dosage and principle, it is to assemble to arteriosclerosis district and rheumatic and rheumatoid focus orientation by reticuloendothelial system, peels off, eliminates focus by phagocytosis then.
The route of administration of preparation of the present invention is as follows: preparation of the present invention needs just can work by blood flow and reticuloendothelial system, anyly blood flow can be entered directly or indirectly or lymphoid route of administration all is suitable for, be preferably intravenously administrable and intraperitoneal administration, in addition can muscle administration and mucosa delivery; Because the M cell in the intestinal wall has the ability of pinocytosis less than the 100nm microgranule, so preparation of the present invention also can be taken orally.Dosage is decided on the kind and the administering mode of contained medicine, the recommended dose when vein or muscle administration: each consumption of being grown up (referring to medicinal nano carbon microsphere content) 10-80mg, every other day once or weekly twice, three month be a course of treatment; Intraperitoneal administration dosage rises to 5000mg; Because preparation toxicity of the present invention is very little, oral dose can according to the state of an illness use the 0.1-5 gram/time.More than be the dosage of medicinal nano carbon microsphere, contained dose all need be lower than the routine dose of clinical use under the situation of its loading anti-tumor active ingredient, looks the state of an illness and grasp flexibly, is generally 1/10～2/10.
Beneficial effect to medicinal nano carbon microsphere and application thereof is described as follows below:
Animal test results shows that particle diameter is that the medicinal nano carbon microsphere of 2-300nm has good bio-guide character, and its guide effect is to the motion of inflammation district, gathering and fixing the realization by the phagocyte in the reticuloendothelial system.This tropism can greatly be strengthened by loading cancer cell multiplication hobby material.Therefore medicinal nano carbon club sees through blood vessel wall and automatically to the focal zone enrichment of tumor under immune effect.Cancerous cell is because its differentiation degree is lower than normal cell, so have stronger phagocytic activity, after medicinal nano carbon microsphere is engulfed by cancerous cell, the metabolism multilated of cancerous cell and cause death, so medicinal nano carbon microsphere itself has the effect that suppresses tumor growth and kill tumor cell.If be carrier absorption and carrier band anti-tumor active ingredient with the medicinal nano carbon microsphere then more strengthened killing the effect of cancerous cell, thereby prepare various antineoplastic targeting medicines, make between tumor blood capillary inside and the tumor cell drug level in the matter reach dozens or even hundreds of times of conventional treatments, greatly strengthen antitumor curative effect, reduced the toxic and side effects of chemotherapy, radiotherapy medicine.Therefore on the basis of using medicinal nano carbon microsphere, the dosage of routine clinical chemotherapy and radiation can drop to the 10-20% of former using dosage, but reach on the contrary than the better therapeutic effect of routine dose, and can reduce usually the infringement normal cell and the immune side effect of being seenly putting, being difficult to avoid in the chemotherapy to greatest extent.Result of study also shows in addition, medicinal nano carbon microsphere of the present invention is atherosis to artery, coronary heart disease, cerebral thrombosis all have prevention effect, infectious disease such as rheumatic and rheumatoid also there is obvious therapeutic effect, its mechanism is because all focal zones have inflammation, the tropism of oriented these focal zone motions of medicinal nano carbon microsphere, looking medicinal nano carbon microsphere in the phagocyte of focal zone is foreign body, inspires and engulfs characteristic, then little by little peels off focus in the process of engulfing.
Below by animal experiment beneficial effect of the present invention is described:
(1) acute toxicity test of medicinal nano carbon microsphere:
1, antitumor agent: the VXC72 that produces with U.S. Carbot company is a raw material preparation medicinal nano carbon microsphere earlier, does not add anti-tumor active ingredient, obtains the medicinal nano carbon microsphere preparation.
2, experimental animal: the CD-1 mice is provided by BJ Univ Hospital's animal center.
3, dosage and administering mode: get and clean the male CD-1 mice of level, the 18-22 gram, totally 60, be divided into 6 groups, 10 every group, under aseptic condition,, 2 times weekly, 0.1ml//time, calculate integral dose by each group dosage tail vein injection administration.
Result of the test is as shown in table 2
Table 2
Number of animals Product A dosage (mg/KG) Death toll (n) Dead % The dosage logarithm Probability unit
??1 ??10 ????160 ??1 ????10 ????2.204 ????3.720
??2 ??10 ????180 ??1 ????10 ????2.255 ????3.720
??3 ??10 ????200 ??2 ????20 ????2.301 ????4.160
??4 ??10 ????220 ??4 ????40 ????2.342 ????4.475
??5 ??10 ????240 ??5 ????50 ????2.380 ????5.000
??6 ??10 ????260 ??5 ????50 ????2.415 ????5.000
Regression equation is: Y=-12.6303+7.3487X, (r=0.9586)
When a=0.01, r is 0.9170, (wherein Y is that probability unit adds the value after 5, and X is the logarithm log x of dosage)
Calculating LD50 is 250.6801mg/kg
Confidence interval during confidence coefficient a=0.05 is: 201.4321≤LD50≤311.9688,0.0950
The result shows that medicinal nano carbon microsphere of the present invention is 250.68mg/Kg to the acute toxicity LD50 of mice, and this toxicity that shows preparation of the present invention is lower, as safe as a house.
(2) inhibition test of medicinal nano carbon microsphere (A preparation):
The purpose of this test is to estimate the tumor-inhibiting action of medicine to the S180 tumor-bearing mice.
Material and method
Tried thing
Being tried name claims: S2
Being tried thing originates: Velgene company
State when being tried thing and receiving: peace is cutd open the bottle encapsulation
Date received: on October 26th, 2004
Date of test: on November 08,26 days to 2004 October in 2004
Laboratory animal: laboratory animal is the CD mice, the SPF-VAF level, and totally 70, male, 18g-22g is provided by our department, the quality certification number: SCXK (capital) 2002-0001.
Feeding environment: raise in SPF level Animal Lab., temperature is 25 ℃ ± 2 ℃, and relative humidity is 55% ± 15%.
The quality certification number: SYXK (capital) 2002-0002.
Feedstuff: mice growth special feed is provided the quality certification number: moving (2000) No. 015 of capital by Beijing section Australia feed corporation,Ltd that pulls together.
Animal grouping and group technology
According to inoculated tumour time order and function and body weight size, carry out random packet, being divided into is 5 groups, 14 every group.
Negative control: the sterile saline group (Hui Da of Datong District pharmaceutcal corporation, Ltd, product batch number: 0311081, specification: 10ml: 90mg)
Positive control: cyclophosphamide group (specification: 0.2g/ props up for Hengrui Medicine Co., Ltd., Jiangsu Prov., lot number 04070821)
Low dose group: 1mg/kg body weight group
Middle dosage group: 2mg/kg body weight group
High dose group: 4mg/kg body weight group
Experimental technique:
1, the preparation of inoculation tumor liquid: tumor-bearing mice is dissected by the sterile working, the numeration of microscopically cell, and being prepared into concentration is that 2 * 107 cells/m), 20ml is used for inoculation altogether.
2, tumor inoculation: sterile working, axil subcutaneous vaccination tumor liquid 0.2ml/ only, i.e. 4 * 106 cell/mices.
3, medication: except that positive controls, respectively organize in inoculation and carried out the tail vein injection administration in the 1st day, the 3rd day, the 6th day, the 8th day, the 10th day; Positive controls lumbar injection ring phosphamidon is pressed the dosage of 30mg/kg, in inoculation administration in the 1st day, the 3rd day, the 6th day, the 8th day, the 10th day.
Detect index:
1, observes animal health condition and death condition every day.
Claim the weight of animals and tumor heavy when 2, experiment finishes.
3, cut open the inspection animal, observe the main organs pathological change.
Data statistics:
The curative effect of solid tumor heavily suppresses percentage rate with tumor and represents.
The heavy suppression ratio %=(1-T/C) * 100% of tumor
Tumour inhibiting rate is greater than 40%, and handle when there were significant differences by statistics, and thinking has the symptom of a trend.
Statistical procedures adopts SPSS for windows to analyze.
Surpass 20% if administration group Mus is dead during the treatment, or average weight decline surpasses 15%, the toxic reaction of expression medicine.
The result
1, medicine sees Table 3 to the influence of the weight of animals and survival state
Table 3 medicine is to the influence of the weight of animals and survival state
Animal body mortality rate % when the initial body weight experiment of group animal finishes
(gram) heavy (gram)
Negative control group 21.8 ± 1.01 27.2 ± 3.74 14.3
Positive controls 21.3 ± 0.98 29.7 ± 1.45---
Low dose group 21.0 ± 1.23 28.5 ± 2.88 5.1
Middle dosage group 21.6 ± 1.11 29.3 ± 1.83 6.4
High dose 21.2 ± 1.17 27.9 ± 5.08 7.4
2, medicine sees Table 4 to the tumor-inhibiting action of tumor-bearing mice
Table 4 medicine is to the tumor-inhibiting action of tumor-bearing mice
The heavy tumour inhibiting rate of group tumor
(gram) %
Negative control group 1.23 ± 0.28---
Positive controls 0.60 ± 0.23 *51.3
Low dose group 0.31 ± 0.22 *75.1
Middle dosage group 0.69 ± 0.32 *44.2
High dose group 0.65 ± 0.55 *47.3
* p＜0.01 is compared with negative control group, has extremely to show difference.
3, the main organs general pathology is observed
High, medium and low dosage group experimental result shows that each internal organs shape of liver, quality, color etc. are normal.
Conclusion
Under this experiment condition, treatment low dose group, middle dosage group and high dose group all have tumor-inhibiting action, and be the highest with the low dose group tumour inhibiting rate, thinks that this medicine has the Seedling head; And high, medium and low dosage group experimental result shows that this drug toxicity is less.
(3) the external test that kills and wounds cancerous cell of medicinal nano carbon microsphere:
Use kidney cancer cell R11, in RPMI-1640, cultivate, A preparation ratio with the 2mg/50ml culture fluid under aseptic condition is added the variation of observing the R11 cell in the Tissue Culture Flask, the result who observes shows, the same day, cancerous cell just stopped growing, next day, cancerous cell was engulfed a large amount of microgranules, began swelling fracture then.Equally distributed microgranule is enriched to cell interior (almost can't see microgranule in the contrast culture bottle background) in culture bottle, illustrate that microgranule initiatively engulfed by cancerous cell, cell quantity begins to reduce, be dissolved into ghost fully through a pericyte, this proof is after cancerous cell initiatively engulfs microgranule, cellular metabolism multilated and cause cell death.
The specific embodiment
The following examples are only in order to further specify the present invention, rather than limit the scope of the invention.
Embodiment 1
The preparation of medicinal nano carbon microsphere:
Select the U.S. VXC72 of CARBOT company medicinal nano carbon microsphere 0.1g for use, add 0.1N hydrochloric acid 5mL, immersion treatment 8 hours, add water 50mL, filter, be washed to PH6 repeatedly, add 0.1N sodium hydroxide 5mL, handled 8 hours, filter, be washed to PH8-9, add 0.1N hydrochloric acid (pact) 5mL, be washed to PH=6-7, filter, drying obtains the finished product medicinal nano carbon microsphere.
Drying is weighed as 0.08 gram, and yield is 80%.Meet the requirement of medicinal nano carbon microsphere of the present invention after testing.
Embodiment 2
Get the medicinal nano carbon microsphere 40mg that embodiment 1 makes, add entry 35mL, stir, add the about 0.5g of surfactant Tween-80, stir, add polyvinylpyrrolidone K30 suspending agent 2g; Stir, add the water standardize solution to 50mL, sonic oscillation 30 minutes stopped 5 minutes, and vibration 4 minutes, messenger drug fully disperseed to become uniform nanometer suspension liquid with nano carbon microsphere, packing, embedding, autoclaving 45 minutes, and lyophilization promptly gets lyophilized powder.
Embodiment 3
Get the medicinal nano carbon microsphere 40mg that embodiment 1 makes, add entry 35mL, stir, add the about 0.5g of surfactant Tween-80, stir, add polyvinylpyrrolidone K30 suspending agent 2g and add 5-Fu 3mg, stir, add the water standardize solution to 50mL, sonic oscillation 15 minutes stopped 5 minutes, vibrated again 15 minutes, messenger drug fully disperses to become uniform nanometer suspension liquid with nano carbon microsphere, and packing, embedding, autoclaving 45 minutes obtain the finished product of formulation in liquid form.
Embodiment 4
Get the medicinal nano carbon microsphere 40mg that embodiment 1 makes, add entry 35mL, stir, add the about 0.5g of surfactant Tween-80, stir, add polyvinylpyrrolidone K30 suspending agent 2g; Add excipient serum albumin 2mg, stir, add the water standardize solution to 50mL, sonic oscillation 15 minutes stopped 5 minutes, vibrated 15 minutes again, and messenger drug fully disperses to become uniform nanometer suspension liquid with nano carbon microsphere, and lyophilization promptly gets the lyophilized powder finished product.
Embodiment 5
Get the medicinal nano carbon microsphere 40mg that embodiment 1 makes, put in the bottle,suction, behind the evacuation, inject 1% calcium folinate aqueous solution 2ml.The agitator shake well adds entry 35mL again in the solution, stir, and adds the about 0.5g of surfactant Tween-80, stirs, and adds polyvinylpyrrolidone K30 suspending agent 2g; Add excipient serum albumin 2mg, stir, add the water standardize solution to 50mL, sonic oscillation 5 minutes stopped 5 minutes, vibrated 4 minutes again, messenger drug fully disperses to become uniform nanometer suspension liquid with nano carbon microsphere, packing, embedding, autoclaving 45 minutes, and lyophilization promptly gets the lyophilized powder finished product.

Claims (10)

1, a kind of have a medicinal nano carbon microsphere that bio-guide character can be used as antitumor drug or carrier, it is characterized in that this medicinal nano carbon microsphere particle diameter is 2nm-1000nm, and wherein 90% diameter of particle is≤300nm, and its specific surface area is 100-3000M 2/ g, ash is lower than 8%, and loss on drying should be lower than 5%, and lead, cadmium, arsenic, mercury content are lower than 20ppm, and avirulence is answered in the inspection of undue toxicity's inspection technique; The microbial limit test inspection always contains the every gram of bacterium number should be lower than 100.
2, a kind of is the antitumor drug of carrier with the described medicinal nano carbon microsphere of claim 1, it is characterized in that its composition and proportioning are as follows:
Medicinal nano carbon microsphere 5-100mg
Directed agents 0-10mg
Suspending agent 0-30mg
Surfactant 0-15mg
Excipient 0-500mg
Water is an amount of.
3, the described antitumor drug of claim 2 is characterized in that: the raw material of preparation medicinal nano carbon microsphere is selected from nano-carbon material; Directed agents is selected from folic acid and its esters; Suspending agent is selected from polyvinylpyrrolidone, arabic gum, tragacanth, polyvinyl alcohol Sodium Tvlose, hydroxypropyl emthylcellulose; Surfactant is selected from tween, polyoxyethylene castor oil, Bo Luoshamu; Excipient is selected from serum albumin or gamma globulin.
4, a kind of is the antitumor drug of carrier with the described medicinal nano carbon microsphere of claim 1, and it is characterized in that: its composition and proportioning are as follows:
Medicinal nano carbon microsphere 5-100mg
Directed agents 0-20mg
Anti-tumor active ingredient 1-100mg
Suspending agent 0-30mg
Surfactant 0-15mg
Excipient 0-500mg
Water is an amount of.
5, the described antitumor drug of claim 4 is characterized in that: the raw material of preparation medicinal nano carbon microsphere is selected from nano-carbon material; Directed agents is selected from folic acid and its esters; Anti-tumor active ingredient is selected from anti-tumor chemotherapeutic medicine, antitumor radiotherapy medicine, suppresses material, anti-tumour antibody or incomplete antibody class, interferon or the anticancer polypeptide class of tumor-blood-vessel growth; Suspending agent is selected from polyvinylpyrrolidone, arabic gum, tragacanth, polyvinyl alcohol Sodium Tvlose, hydroxypropyl emthylcellulose; Surfactant is selected from tween, polyoxyethylene castor oil, Bo Luoshamu; Excipient is selected from serum albumin or gamma globulin.
6, the described antitumor drug of claim 2-5 is characterized in that: the raw material of preparation medicinal nano carbon microsphere is VXC72; Directed agents is a calcium folinate; Anti-tumor active ingredient is anti-tumor chemotherapeutic and radiotherapy medicine; Suspending agent is a polyvinylpyrrolidone; Surfactant is Bo Luoshamu; Excipient is a serum albumin.
7, the described preparing anti-tumor medicine method of claim 2-5, it is characterized in that: this method comprises the steps:
(1) prepares the medicinal nano carbon microsphere that conforms to quality requirements;
(2) add suspending agent and/or surfactant and anti-tumor active ingredient by proportioning, mix homogeneously,
(3) add directed agents by proportioning, sonic oscillation was handled 30～60 minutes, autoclaving 30～60 minutes; Packing, embedding, autoclaving 45 minutes obtain the finished product of formulation in liquid form;
(4) add excipient by proportioning under aseptic condition, lyophilization promptly gets lyophilized powder type finished product.
8, the application of the described medicinal nano carbon microsphere of claim 1 in preparation treatment cancer drug.
9, the application of the described medicinal nano carbon microsphere of claim 1 in preparation treatment cardiovascular and cerebrovascular diseases medicament.
10, the application of the described medicinal nano carbon microsphere of claim 1 in preparation treatment rheumatism medicine.
CNB2004100971505A 2004-12-13 2004-12-13 Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer Expired - Fee Related CN1274366C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNB2004100971505A CN1274366C (en) 2004-12-13 2004-12-13 Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer
PCT/CN2005/002112 WO2006063506A1 (en) 2004-12-13 2005-12-07 Utilization for carbon nanosphere in anti-cancer medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100971505A CN1274366C (en) 2004-12-13 2004-12-13 Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer

Publications (2)

Publication Number Publication Date
CN1634588A true CN1634588A (en) 2005-07-06
CN1274366C CN1274366C (en) 2006-09-13

Family

ID=34847914

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100971505A Expired - Fee Related CN1274366C (en) 2004-12-13 2004-12-13 Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer

Country Status (2)

Country Link
CN (1) CN1274366C (en)
WO (1) WO2006063506A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127829A1 (en) * 2010-04-16 2011-10-20 Wang Zhong Use of carbon nanoparticles as externl applied medicament for treating hemorrhoid
CN102370989A (en) * 2010-08-19 2012-03-14 逢甲大学 Medicinal composition for treating urinary system diseases
CN112494655A (en) * 2020-12-24 2021-03-16 中南大学湘雅医院 Nano carbon-drug composite system and preparation method and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100215960A1 (en) 2009-02-24 2010-08-26 Toyota Motor Engineering & Manufacturing North America, Inc. Hollow carbon spheres
CN103043646B (en) * 2012-12-21 2014-06-04 浙江大学 Method for preparing small solid carbon ball and carbon ball prepared thereby
CN113415798B (en) * 2021-05-12 2023-02-24 江西农业大学 Preparation method of phosphorus-doped microporous, mesoporous and macroporous coexisting grade pore structure carbon nanospheres

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509116A (en) * 1998-01-16 2002-03-26 ザ・ジョーンズ・ホプキンス・ユニバーシティ Genetic immunity by simultaneous transport of nucleic acids and cytokines in a single solvent

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127829A1 (en) * 2010-04-16 2011-10-20 Wang Zhong Use of carbon nanoparticles as externl applied medicament for treating hemorrhoid
CN102370989A (en) * 2010-08-19 2012-03-14 逢甲大学 Medicinal composition for treating urinary system diseases
CN102370989B (en) * 2010-08-19 2013-05-29 逢甲大学 Medicinal composition for treating urinary system diseases
CN112494655A (en) * 2020-12-24 2021-03-16 中南大学湘雅医院 Nano carbon-drug composite system and preparation method and application thereof

Also Published As

Publication number Publication date
WO2006063506A1 (en) 2006-06-22
CN1274366C (en) 2006-09-13

Similar Documents

Publication Publication Date Title
CN1195511C (en) The use of fumaric acid derivatives in transplant medicine
CN1155368C (en) Powdery composition for nasal administration
CN100340295C (en) Oral administered compound colloid pectin bismuth preparation and its preparing process
CN1895237A (en) Officinal magnolia phenol lipid frozen dried powder preparation and its use in preparing drug for cancers
CN1102324A (en) Pharmaceutical composition
CN1274366C (en) Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer
CN1706371A (en) Efficient sword-like iris seed prepn and its prepn process
CN1686165A (en) Medical nano-carbon tube composition, preparation method and its application
CN1491126A (en) Method of cancer therapy
CN1429558A (en) Mannosan peptide injection and its preparation and use method
CN1280855A (en) Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose
CN1109034C (en) Composition of gambogic acid compounds with anticancer activity and its preparing process
CN1843354A (en) Injectable pharmaceutical composition containing faropenem
CN1907266A (en) Potassium dehydroandrographolide succinate/potassium dehydroandrographolide succinate liposome composition and production method thereof
CN1732936A (en) Nimodipine emulsion injection liquid and method for preparing the same
CN1973826A (en) Injection containing lipoid microsphere of etoposide and its prepn process
CN1765364A (en) Lipid formulation of nolatrexed dihydrochloride and its preparation method
CN1748758A (en) Dragon's blood gel preparation and its preparing method
CN1210023C (en) Carboplatin precursor liposome injection and preparing process thereof
CN1273195C (en) Carbonized pollen and its application for preparing medicine to treat cancer
CN1245407C (en) Composition of garcinolic acid compounds, its preparing process and medical composition using it as active component
CN1281593C (en) Immune regulation and biological therapeutic function of benzo-isoselenazole derivatives
CN1742783A (en) Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method
CN1543933A (en) Curcumin injection and method for preparing the same
CN101062040A (en) Stable type cucurbitacin liquid formula and the agent thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060913

Termination date: 20111213